Your browser doesn't support javascript.
loading
Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors.
Ye, Na; Xu, Qingfeng; Li, Wanwan; Wang, Pingyuan; Zhou, Jia.
Afiliação
  • Ye N; Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
  • Xu Q; Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
  • Li W; Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, United States.
  • Wang P; Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
  • Zhou J; Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
Curr Top Med Chem ; 19(23): 2114-2127, 2019.
Article em En | MEDLINE | ID: mdl-31475899
The Ras proteins play an important role in cell growth, differentiation, proliferation and survival by regulating diverse signaling pathways. Oncogenic mutant K-Ras is the most frequently mutated class of Ras superfamily that is highly prevalent in many human cancers. Despite intensive efforts to combat various K-Ras-mutant-driven cancers, no effective K-Ras-specific inhibitors have yet been approved for clinical use to date. Since K-Ras proteins must be associated to the plasma membrane for their function, targeting K-Ras plasma membrane localization represents a logical and potentially tractable therapeutic approach. Here, we summarize the recent advances in the development of K-Ras plasma membrane localization inhibitors including natural product-based inhibitors achieved from high throughput screening, fragment-based drug design, virtual screening, and drug repurposing as well as hit-to-lead optimizations.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Oncogênica p21(ras) / Membrana Celular / Avaliação Pré-Clínica de Medicamentos / Neoplasias / Antineoplásicos Fitogênicos Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Oncogênica p21(ras) / Membrana Celular / Avaliação Pré-Clínica de Medicamentos / Neoplasias / Antineoplásicos Fitogênicos Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article